45 completed, 16 unknown, 14 terminated, 8 active not recruiting. 101 Phase 3, 21 Phase 2.
Follow Heart Valve Diseases: new trials by email Literature Review of Heart Valve Diseases trials Research Report on Heart Valve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM) Mavacamten, Placebo - Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 500 | 2026-12-29 | 2026-11-17 |
| BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy BHB-1893, Metoprolol - Cardiomyopathy, Hypertrophic Obstructive | Phase 3 | Recruiting | Braveheart Bio, Inc. | 210 | 2026-09-02 | 2026-11-10 |
| Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot Valsartan, Placebo - Atrial Functional Mitral Regurgitation | Phase 2 / Phase 3 | Recruiting | Jonathan Beaudoin | 50 | 2026-07-13 | 2026-08-20 |
| Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement Wegovy ®, Placebo - Aortic Stenosis, Heart Failure | Phase 3 | Not yet recruiting | Leiden University Medical Center | 826 | 2026-04-01 | 2025-07-29 |
| Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR Apixaban, Warfarin - Valve Disease, Heart, Atrial Fibrillation (AF) | Phase 3 | Not yet recruiting | Meshalkin Research Institute of Pathology of Circulation | 120 | 2026-02-01 | 2026-02-25 |
| LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain. Anticoagulant treatment Rivaroxaban, Best medical therapy - Hypertrophic Cardiomyopathy (HCM) | Phase 3 | Recruiting | Rennes University Hospital | 532 | 2026-01-07 | 2026-06-12 |
| DIrect Oral Anticoagulation and Bioprothesis Aortic Valve Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day - Aortic Valve Disease | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 1500 | 2025-09-01 | 2025-06-12 |
| A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy HRS-1893 Tablets, HRS-1893 Placebo Tablets - Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | Shandong Suncadia Medicine Co., Ltd. | 228 | 2025-08-11 | 2026-08-24 |
| A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy BAY3723113 - Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | Bayer | 36 | 2025-06-30 | 2026-10-23 |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study Ataciguat, Placebo - Moderate Aortic Valve Stenosis | Phase 2 / Phase 3 | Recruiting | Kardigan, Inc. | 1276 | 2025-06-27 | 2026-07-06 |
| Antagonization of Heparin With Protamine Sulfate After TAVI Antagonization of heparin with protamine sulfate - Aortic Valve Stenosis, Heart Valve Diseases | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 940 | 2025-05-25 | 2025-08-22 |
| Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring ATP-C135, ATP-C75 - Hypertrophic Cardiomyopathy | Phase 3 | Not yet recruiting | Yonsei University | 100 | 2025-03-01 | 2025-03-13 |
| Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia Inclisiran, Placebo - Familial Hypercholesterolemia - Homozygous | Phase 3 | Recruiting | Novartis Pharmaceuticals | 9 | 2025-02-28 | 2026-07-24 |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia Inclisiran, Placebo - Familial Hypercholesterolemia - Heterozygous | Phase 3 | Recruiting | Novartis Pharmaceuticals | 60 | 2024-12-09 | 2026-05-15 |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy Sotagliflozin, Placebo - Obstructive Cardiomyopathy, Hypertrophic, Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Active not recruiting | Lexicon Pharmaceuticals | 500 | 2024-09-24 | 2026-08-26 |
| The Role of SGLT2i in Management of Moderate AS Empagliflozin 10 MG - Moderate Aortic Valve Stenosis | Phase 2 / Phase 3 | Completed | University of East Anglia | 104 | 2024-05-30 | 2026-07-28 |
| A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy Mavacamten, Placebo - Cardiomyopathy, Hypertrophic | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 44 | 2024-04-17 | 2025-12-19 |
| Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis PCSK9 inhibitors and statins with or without ezetimibe, Statins with or without ezetimibe - Aortic Stenosis | Phase 3 | Recruiting | Beijing Anzhen Hospital | 160 | 2024-03-22 | 2024-05-09 |
| An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM Aficamten - Obstructive Hypertrophic Cardiomyopathy | Phase 3 | Completed | Corxel Pharmaceuticals | 40 | 2023-11-14 | 2026-01-21 |
| Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Enavogliflozin, Placebo - Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | Phase 3 | Active not recruiting | Asan Medical Center | 541 | 2023-10-25 | 2025-12-29 |
Showing 20 of 101. Sign in to see all of them.
Aortic Valve Stenosis (37) · Cardiomyopathy, Hypertrophic (27) · Heart Failure (10) · Mitral Valve Insufficiency (9) · Atrial Fibrillation (6) · Cardiovascular Diseases (6) · Coronary Artery Disease (6) · Hypertrophy, Left Ventricular (6) · Tricuspid Valve Insufficiency (5) · Aortic Valve Disease (4) · Mitral Valve Stenosis (4) · Aortic Valve Insufficiency (3) · Bicuspid Aortic Valve Disease (3) · Heart Diseases (3)
Heart Diseases (98) · Cardiovascular Diseases (95) · Aortic Valve Disease (67) · Ventricular Outflow Obstruction (35) · Aortic Stenosis, Subvalvular (27) · Aortic Valve Stenosis (27) · Cardiomyopathies (27) · Pathological Conditions, Signs and Symptoms (21) · Vascular Diseases (16) · Pathologic Processes (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Arterial Occlusive Diseases (7) · Arteriosclerosis (7) · Cardiomegaly (7)
MYK-461 (8) · apixaban (5) · Aspirin (4) · Atorvastatin (4) · Metoprolol (4) · Rivaroxaban (4) · Warfarin (4) · Clopidogrel (3) · Saline Solution (3) · empagliflozin (3) · ALN-PCS (2) · Atenolol (2) · Colchicine (2) · Dexmedetomidine (2) · Perhexiline (2)
Assistance Publique - Hôpitaux de Paris (6) · Bristol-Myers Squibb (6) · Asan Medical Center (3) · Cytokinetics (3) · Charite University, Berlin, Germany (2) · National Institute of Cardiology, Warsaw, Poland (2) · Novartis Pharmaceuticals (2) · Oslo University Hospital (2) · Ottawa Heart Institute Research Corporation (2) · Rajaie Cardiovascular Medical and Research Center (2) · Sorin Group USA, Inc. (2) · University Hospital Birmingham (2) · University Hospital, Bordeaux (2) · Artivion Inc. (1) · Astana Medical University (1)
United States (25) · France (24) · Canada (21) · Germany (18) · United Kingdom (17) · Netherlands (14) · China (13) · Italy (13) · Spain (12) · Israel (11) · Denmark (10) · Poland (10) · Czechia (9) · Portugal (8) · Brazil (7)
Jian-an Wang, MD,PhD (2) · Ade Meidian Ambari, MD,FIHA (1) · Alex Zapolanski, MD (1) · Ali Khoynezhad, MD (1) · Alibek Kh Mustafin, Professor (1) · An Aldia Asrial, MD (1) · Andre Duraes, PhD (1) · Andrew Maitland, MD (1) · Arturo Evangelista-Masip, MD, PhD, Professor (1) · Aun-Yeong Chong, MD, MRCP (1) · Brian P O'Neill, MD (1) · Carolyn Y Ho, MD (1)
PMID 42636950, PMID 39217450, PMID 42624353, PMID 16500110, PMID 16539843, PMID 18341239, PMID 18765432, PMID 19580719, PMID 20413039, PMID 20628774, PMID 20659762, PMID 21353251, PMID 22147903, PMID 22155702, PMID 22440214, PMID 22818065, PMID 22869821, PMID 23316326, PMID 23357717, PMID 23713888, PMID 24004961, PMID 24173271, PMID 24780909, PMID 24824357, PMID 24903982, PMID 25048345, PMID 25217488, PMID 25240525, PMID 25301859, PMID 25438232, PMID 25469804, PMID 25540059, PMID 25685360, PMID 26361154, PMID 26477635, PMID 26489804, PMID 26602073, PMID 27085434, PMID 27196464, PMID 27208464, PMID 27486164, PMID 27491438, PMID 27590665, PMID 28319871, PMID 28400935, PMID 28455295, PMID 28698175, PMID 28797414, PMID 29180457, PMID 29361285
2023 (4), 2015 (2), 2017 (1), K23HL078901 (1), U01HL084904 (1)